Journal article
New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations
EP Harausz, AJ Garcia-Prats, JA Seddon, HS Schaaf, AC Hesseling, J Achar, J Bernheimer, AT Cruz, L D'Ambrosio, A Detjen, SM Graham, J Hughes, S Jonckheere, BJ Marais, GB Migliori, L McKenna, A Skrahina, M Tadolini, P Wilson, J Furin
American Journal of Respiratory and Critical Care Medicine | AMER THORACIC SOC | Published : 2017
Abstract
It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the..
View full abstractGrants
Awarded by Medical Research Council